A Phase II Evaluation Of Triapine (NCI-Supplied Agent: NSC 663249, IND 68338) In Combination With Cisplatin (Commercially Available: NSC 119875) In The Treatment Of Recurrent Or Persistent Platinum-Resistant Ovarian Or Primary Peritoneal Carcinoma.

Trial Profile

A Phase II Evaluation Of Triapine (NCI-Supplied Agent: NSC 663249, IND 68338) In Combination With Cisplatin (Commercially Available: NSC 119875) In The Treatment Of Recurrent Or Persistent Platinum-Resistant Ovarian Or Primary Peritoneal Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2013

At a glance

  • Drugs Cisplatin (Primary) ; OCX 191 (Primary)
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Jul 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov.
    • 04 Sep 2006 Status change
    • 19 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top